A Phase 1 Open-Label Study to Evaluate the Safety Tolerability and Activity of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

A Phase 1 Open-Label Study to Evaluate the Safety Tolerability and Activity of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Recruiting
99 years or below
All
Phase 1
10 participants needed
1 Location

Brief description of study

This study is being done to see how safe the investigational new drug, AK002 is and how it affects your EG and/or EGE symptoms and the number of eosinophils in the stomach and the small intestine. This study will also be used to identify the best premedication and dose regimen to use in patients in future research studies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Gastroenteritis
  • Age: 99 years or below
  • Gender: All


Updated on 19 Feb 2024. Study ID: 833817

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.